Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Henrique, Rui ^a,b   Oliveira, Ana I ^a   Costa, Vera L ^a   Baptista, Tiago ^a   Martins, Ana T ^a   Morais, António ^a   Oliveira, Jorge ^a   Jerónimo, Carmen ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

CpG island hypermethylation; Epigenetic regulation; Histone post translational activation repression marks; MDR1; P gp; Prostate

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE; HISTONE H3; HISTONE H4; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; TRICHOSTATIN A;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENETIC REGULATION; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MDR1 GENE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN METHYLATION; QUANTITATIVE ASSAY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; P-GLYCOPROTEIN; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84890290106     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-898     Document Type: Article

References (41)

1. Shukla S, Ohnuma S, Ambudkar SV. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 2011, 12(5):621-630.
2. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003, 55(1):3-29.
3. Tiwari AK, Sodani K, Dai CL, Ashby CR, Chen ZS. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 2011, 12(4):570-594.
4. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22(47):7468-7485.
5. Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 1987, 262(36):17432-17436.
6. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990, 265(1):506-514.
7. Chen GK, Sale S, Tan T, Ermoian RP, Sikic BI. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol 2004, 65(4):906-916.
8. Baker EK, El-Osta A. Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing. Methods Mol Biol 2010, 596:183-198.
9. Cornwell MM. The human multidrug resistance gene: sequences upstream and downstream of the initiation site influence transcription. Cell Growth Differ 1990, 1(12):607-615.
10. Jin S, Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 1998, 18(7):4377-4384.
11. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, et al. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 2004, 64(17):5956-5962.
12. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005, 11(18):6582-6588.
13. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004, 64(6):1975-1986.
14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
16. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011, 60(4):753-766.
17. Bhangal G, Halford S, Wang J, Roylance R, Shah R, Waxman J. Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 2000, 5(3):118-121.
18. Kawai K, Sakurai M, Sakai T, Misaki M, Kusano I, Shiraishi T, Yatani R. Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett 2000, 150(2):147-153.
19. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8(4):286-298.
20. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012, 22(1):50-55.
21. Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 2007, 177(3):822-831.
22. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007, 447(7143):407-412.
23. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, Teixeira MR, Lopes C, Sidransky D. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 2004, 10(12 Pt 1):4010-4014.
24. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004, 10(24):8472-8478.
25. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011, 21(3):502-517.
26. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012, 13(10):679-692.
27. Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, Bogdanowicz JF, Van Der Kwast TH, Schroder FH, Mickisch GH. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 2001, 165(1):130-135.
28. Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jeronimo C. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) 2006, 84(11):911-918.
29. Costa VL, Henrique R, Danielsen SA, Eknaes M, Patricio P, Morais A, Oliveira J, Lothe RA, Teixeira MR, Lind GE, et al. TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics 2011, 6(9):1120-1130.
30. Chen KG, Wang YC, Schaner ME, Francisco B, Duran GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, et al. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Res 2005, 65(20):9388-9397.
31. Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, Kawakami T, Tanaka Y, Pookot D, Chen Z, et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 2007, 13(9):2541-2548.
32. Okino ST, Pookot D, Majid S, Zhao H, Li LC, Place RF, Dahiya R. Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer. Mol Carcinog 2007, 46(10):839-846.
33. Scotlandi K, Manara MC, Serra M, Benini S, Maurici D, Caputo A, De Giovanni C, Lollini PL, Nanni P, Picci P, et al. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene 1999, 18(3):739-746.
34. Mackler NJ, Pienta KJ. Drug insight: use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2005, 2(2):92--100. quiz 101 p following 112.
35. Epstein JI. An update of the Gleason grading system. J Urol 2010, 183(2):433-440.
36. Eble J, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization and International Agency for Research on Cancer: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs 2004, IARC: Lyon.
37. Pearson HSD. DNA extraction from tissue. Methods Mol Biol 2003, 226:233-224.
38. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M. DNA methylation: bisulphite modification and analysis. Nat Potoc 2006, 1:2353-2364.
39. Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 1996, 24(24):5064-5066.
40. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, Rodrigues A, Magalhaes JS, Oliveira J, Lothe RA, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010, 16(23):5842-5851.
41. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999, 59(15):3730-3740.